

# CURRENT THERAPEUTIC RESEARCH

## RESEARCH LETTERS

These are planned or follow-up subgroup analyses of previously published randomized trials. Alternatively, research letters can present novel research that may stimulate further investigation or alert readers to clinically relevant but preliminary findings. The submission should include an accurate and succinct title; an unstructured abstract; an introduction that specifies the rationale for the study, beginning with a statement similar to "This communication provides..."; the body of the letter, describing the methods, results, and conclusion; and references.

*Abstract: 100 words*

*References: 15*

*Text: 1000-1500 words*

*Graphics: 2*

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### **Conflict of Interest**

At the end of the text and preceding the references section, under a subheading "Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the

study sponsors had no such involvement, the authors should so state. As a guideline see the ICMJE form for disclosure of Potential Conflicts of Interest at:

[http://www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) In order to maintain the double blind peer review process, we recommend that first and last initials are used in place of author names within this section.

## Units

Follow internationally accepted rules and conventions: use the international system of units (SI).

If other units are mentioned, please give their equivalent in SI.

## Essential Title Page Information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address.  
Superscript Arabic numerals are used for such footnotes